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Abstract 
Mycosis fungoides is a primary cutaneous T-cell lymphoma with unfavorable prognosis for the 
advanced stages of the disease. Refractory disease and advanced-stage disease require systemic 
therapy. 
We report on a rare case of an atypical predominantly CD8+ folliculotropic mycosis fungoides (MF), a 
subtype of MF with poorer prognosis, in a 59-year-old woman, initially diagnosed with MF restricted 
to the skin- of T3N0M0B0/stage IIB according to the current WHO/EORTC classification. First-line 
treatment with local percutaneous radiotherapy in combination with systemic interferon alfa-2a 
resulted in complete remission. However, 21 months later the disease progressed to 
T3N0M1B0/stage IVB with development of cerebral manifestation and thus very poor prognosis. 
Allogeneic stem cell transplantation (SCT) was not a therapeutic option due to the lack of a suitable 
donor. We initiated methotrexate and cytarabin chemotherapy, followed by high-dose 
chemotherapy with thiotepa and BCNU with autologous SCT. Despite rapid response and complete 
remission of the cerebral lesions, disease recurrence of the skin occurred soon after. Interestingly, 
re-administration of interferon alfa-2a as a maintenance treatment after the salvage autologous SCT 
resulted in a durable complete remission during the follow-up period of currently 13 months after 
autologous SCT.   
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Introduction 
Cutaneous T-cell lymphomas represent a group of extranodal non-Hodgkin lymphomas originating 
from malignant clonal transformation of skin homing and/or skin resident-T cells1. Mycosis fungoides 
(MF) encompasses approximately 60% of all cutaneous T-cell lymphomas and is therefore the most 
frequent type2. Median age of first presentation is 57 years with a male/female ratio of 2:13. 
Approximately, 0.36-0.9 per 100,000 persons per year are diagnosed with MF4,5. MF can have an 
indolent course with a 5-year survival rate of nearly 100% in stage IA to less than 10% in stage IVB 
disease6. MF exhibits a broad and increasing spectrum of clinical, histological, and 
immunophenotypic variants, but on average, 10% of all stage IA MF- patients with skin- limited 
patches or plaques will  progress to more advanced disease7. On the contrary, folliculotropic MF is 
associated with impaired prognosis with 5- and 15-year survival rates of approximately 60-80% and 
41%, respectively8-12. Most often, extracutaneous involvement occurs in the liver, spleen and 
lungs13,14, but the occurrence of cerebral involvement in MF is known to be very rare, and 
intraparenchymal disease is even less frequent than meningeal disease15.  
We report on a patient with atypical MF with central nervous system involvement, in whom salvage 
high-dose chemotherapy with autologous SCT and interferon alfa-2a maintenance therapy resulted 
in durable complete remission.  
 
Case report 
A 59-year-old woman was referred to our hospital with newly diagnosed MF. Five months before, 
she first noticed a skin lesion rapidly growing on the right side of her chin and transiently enlarged 
right submandibular lymph nodes without systemic symptoms (Figure 1A). The patient’s medical 
history was unremarkable, with the exception of an uneventful complete excision of a basal cell 
carcinoma on the nose several months before. Skin biopsy of the above described lesion revealed 
folliculotropic small-sized predominantely CD8+ T-cell lymphoma compatible with MF, plaque stage. 
Histology showed proliferation of atypical lymphocytes located to hair follicules without either mucin 
deposition nor interfollicular epidermotropism. Immunohistochemistry demonstrated expression of 
CD3, CD5 and predominantly CD8 rather than CD4 expression on hair follicules infiltrating atypical 
lymphocytes (Figure 1B). Moreover, complete dermatological examination revealed multiple, 
disseminated, hitherto disregarded by the patient patches, plaques and agminated papules (Figure 
1C).  Lymph node sonography and whole-body combined positron-emission tomography and 
computed tomography (PET-CT) showed no extracutaneous involvement. The patient was thus 
initially diagnosed with a skin-limited MF of folliculotropic subtype (one nodular facial lesion and 
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multiple disseminated skin patches on the anterior and posterior trunk), and classified as a 
T3N0M0B0/stage IIB according to the current WHO/EORTC classification.  
External-beam radiotherapy with a fractionated total dose of up to 32Gy was used as a first-line 
treatment of the facial nodule and systemic interferon alfa-2a 3x3Mio per week and PUVA therapy 
for the disseminated patches was applied. This treatment resulted in a full remission of the MF 16 
months after disease onset. However, 5 months later new subtle depressive symptoms, including 
mild fatigue and a tendency for a decreased willingness to engage in conversation and make 
decisions occurred. At first, we interpreted those symptoms as a side effect of interferon alfa-2a and 
stopped the treatment. Nevertheless, within a few weeks, the patient developed pronounced 
personality changes and had difficulties finding words.  
Magnetic resonance imaging (MRI) of the brain showed T2 hyperintense large lesion in the left 
frontal lobe with involvement of the corpus callosum and basal ganglia (Figure 2A). 
Neuropathological examination of stereotactic brain biopsy of the frontal lobe demonstrated diffuse 
infiltration of the CNS tissue by a small round blue cell neoplasm with increased mitotic activity as 
well as increased apoptosis. The findings were compatible with brain metastasis of mycosis 
fungoides. The neoplastic cells were immunoreactive for CD3, CD7, TCR-β F1 (fig. 2B) and TIA1 (not 
shown). Scattered neoplastic cells showed CD2 and CD5 immunoreactivity, indicating antigen loss 
(see figure 2B). Only few cells showed weak CD8 positivity (not shown), CD30 remained negative (fig 
2B). Staining for CD4 and CD56 showed extremely high background immunoreactivity in the CNS 
tissue and were classified as «inconclusive» (not shown). Proliferation index (Mib-1) was >95% (fig. 
2B). Neoplastic cells were negative for CD20, TdT, CD79a, TCL-1, Perforin, TCR-gamma, ALK1 as well 
as for Epstein–Barr encoding region (EBER) in situ hybridization (not shown).  
MF progression to T3N0M1B0/stage IVB is associated with a very bad prognosis. Since no matching 
stem cell donor for allogeneic SCT was available, we initiated methotrexate and cytarabin 
chemotherapy, followed by high-dose chemotherapy with thiotepa and BCNU with autologous SCT.  
Despite rapid response and complete remission of the cerebral lesions (Figure 2C), histologically 
confirmed disease recurrence of the skin occurred 10 months after the autologous SCT (Figure 2D 
and E). Quantitative assessment of the total skin disease burden post-autoSCT with the modified 
severity weighted assessment tool (mSWAT) scored 15 out of 400 points (Figure 3A).  
Interestingly, re-administration of interferon alfa-2a 3x3Mio per week as a maintenance treatment 
after the salvage autologous SCT resulted in a durable complete remission (mSWAT 0) during the 
follow-up period of currently 17 months after autologous SCT (Figure 3B).  All biopsied patient’s skin 
and brain lesions displayed an identical unequivocally monoclonal T-cell population (Figure 3C).  
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Discussion 
This is rare manifestation of an atypical, predominantly CD8+ primary cutaneous T cell lymphoma 
with subsequent cerebral involvement. According to the current WHO/EORTC classification, mycosis 
fungoides (MF) and primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (pcAETCL) 
represent the two major differential diagnosis16. pcAETCL may often spread to the central nervous 
system and has an estimated 5-year survival of 0%17. To establish the diagnosis of pcAETCL, sets 
of diagnostic criteria, based on combination of clinical, histopathological, and 
immunohistochemical features have been suggested18. However, no specific criterion 
pathognomonic for pcAETCL exists, its clinical features can be indistinguishable from advanced MF, 
and exclusion of MF is crucial before establishing the diagnosis of pcAETCL19-21.  In this particular 
case, the clinical appearance with one non-ulcerative nodular facial lesion and multiple disseminated 
skin patches and plaques on the anterior and posterior trunk was typical for MF and did not favor 
pcAETCL20. Furthermore, diagnostic criteria for MF were formally fulfilled and the clinical course of 
the disease, including the clinical manifestation of the relapse lesions post auto-SCT strongly favored 
the diagnosis of MF 22-24. In MF patients, cerebral involvement is rare and presents most frequently as 
cranial nerve dysfunction or fluctuation of higher cognitive functions25. In line with this, loss of 
eagerness to engage in conversations dominated the clinical appearance of the patient presented 
here. The risk of cerebral involvement in MF patients increases with large-cell transformation (LCT)16. 
Interestingly, LCT could not be detected in the present case. However, in contrast to our patient who 
did not show any extracutaneous organ involvement other than the brain, most MF patients with 
cerebral disease without LCT develop significant skin lesions or visceral involvement before disease 
spread to the central nervous system (CNS)25. The incidence of CNS involvement in MF clinical studies 
is less than 1.3-1.6%13,26, whereas autopsy series found post mortem CNS involvement in 10-15% of 
MF patients25,27,28. Stein et al. found MF patients with two or more of the T3-4, N3, M1 and B1 
classification factors to have a one in six chance for cerebral involvement and defined a median 
survival with treatment of 3 months after onset of neurologic symptoms13. Patients who refused 
treatment died on average within one month13. Recently Yang et al reported a systemic review on 77 
MF patients with CNS metastasis, 10 of whom achieved complete remission. In this analysis, the 
median time between the diagnosis of MF and the detection of cerebral metastasis was 36 months. 
None of those patients received autologous SCT, most common treatments being radiation, 
intrathecal methotrexate and single agent chemotherapy, none of them associated with a different 
clinical outcome29.  
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As a sensitive and specific detector of cerebral metastasis MRI, CT scan and cerebrospinal fluid 
analysis were tested, but none of these was found to be completely reliable.29 Some researchers 
have suggested that elevated β2-microglobulin and lactate dehydrogenase levels (LDH) may be 
markers of CNS involvement13,27,30. However, while elevated serum LDH is a known marker of poor 
prognosis in MF31, it is still unclear if LDH and serum β2-microglobulin could be useful as routine 
parameters in the diagnostic and follow-up of MF with respect to cerebral manifestations. Whereas 
prophylactic therapy such as brain radiation is applied to patients with non-Hodgkin lymphoma32,33, it 
is not common in patients with MF34. As Stein et al. suggest, patients at high-risk of CNS involvement 
could benefit from whole brain and proximal cranial nerve radiation therapy at little expense and 
toxity13.  
The management of advanced MF is currently based on mono- or combinational therapy, including 
interferon-α, retinoids (bexarotene), photopheresis, chemotherapy, radiotherapy, as well as targeted 
therapies such as the monoclonal antibody brentuximab35-37. Most treatment options only induce 
remissions of limited duration29-31. An additional challenge in the management of advanced MF 
patients is their severely compromised immunity, with an aberrant TH2- phenotype as well as 
abnormal natural killer cell-, cytotoxic T-cell- and dendritic-cell function9,38,39.  
SCT is a curative treatment option for advanced MF, with overall survival or relapse- free survival 
significantly longer in patients with allogenic than with autologous SCT40. MF patients receiving 
allogeneic SCT further benefit from the graft versus leukemia effect, mediated by allogeneic donor T-
cells that target and eliminate tumor cells.  
The very poor/unfavorable prognosis of the cerebral involvement in the case of the patient 
presented here, necessitated an immediate treatment, but a suitable donor for allogeneic SCT could 
not be identified in due time. As a consequence, we opted for high dose chemotherapy with 
autologous SCT.  In cutaneous T-cell lymphoma, especially MF, this approach usually induces a 
temporary remission, but relapses follow early, from 61 days to 15 months post transplantation40-44. 
Moreover, the short time to relapse is associated with a shorter survival time30. 
In line with this data, our patient's MF relapsed early after the autologous SCT, but in a less 
aggressive form, with skin limited patch form of the disease only. Following re-administration of 
interferon alfa-2a 3x3Mio per week as maintenance therapy after the salvage autologous SCT, a 
durable complete remission for a follow-up period of currently 17 months after SCT was achieved. 
Clinical research assessing the efficacy of alfa-type IFNs in the management of CTCL have considered 
two forms of recombinant IFN alfa, IFN alfa-2a (Roferon®) and IFN alfa-2b (Intron-A®) and its 
pegilated versions Pegasys® and PegIntron®, respectively45. IFN alfa-2a and IFN alfa-2b share nearly 
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identical structures, seem to bind to the same type I IFN receptor and to have similar efficacy in the 
treatment of CTCL. However, while Roferon® is no longer manufactured in the United States, it is 
currently the only IFN alfa officially licensed for the treatment of CTCL in Europe, hence our decision 
to use interferon alpha-2a versus 2b in this particular case45,46. 
Reported data on long-term favorable post-autologous SCT outcome in advanced MF is scarce. Less 
aggressive disease has been reported after autologous SCT42. Di et al. reported a 25-year-old patient 
with multiple skin lesions, lymphadenopathy and neurological symptoms, who received autologous 
STC after progression on chemotherapy. Fourteen years after, this patient was still in complete 
remission47. Our patient has now an ongoing 17-month remission. In summary, we report on an 
unusual case of MF with cerebral involvement, in which a durable complete remission was achieved 
upon autologous SCT and interferon alfa-2a maintenance therapy.  
 
Figure Legends: 
Figure 1: A) Clinical appearance of the skin nodule in the right mandibular region. B) Folliculotropic 
MF with infiltration of a hair follicle by small- to medium-sized lymphocytes without mucin 
deposition and some nuclear atypia (yellow arrowheads) (H&E, upper part of the image). 
Lymphocytes showed CD3 and predominantly CD8 positivity in the fraction of the folliculotropic 
lymphocytes (IHC, lower part of the image). C) Initial clinical manifestation of mycosis fungoides MF 
with multiple, disseminated erythematous patches, plaques and papules. 
 
Figure 2: A) Magnetic resonance imaging (MRI) before autologous SCT of the brain with T2 
hyperintense large lesion in the left frontal lobe with involvement of the corpus callosum and basal 
ganglia. B) Stereotactic brain biopsy of the frontal lobe: H&E staining demonstrates diffuse 
infiltration of the CNS tissue by a small round blue cell neoplasm with increased mitotic activity 
(yellow arrowheads) and increased apoptosis. Immunoreactivity of the neoplastic cells for CD3, CD7, 
TCR-beta F1 and TIA1 (not shown). Partial antigen loss for CD2 and CD5; no immunoreactivity for 
CD30. Proliferation index (MIB-1) >95%. C) MRI after autologous SCT of the brain shows complete 
remission of the brain metastasis in the left frontal lobe. D) Clinical appearance of recurrent lesion 
after auto-SCT; erythematous patch on the left upper arm. E) Skin biopsy of the recurrent lesion 
depicted in (D) with band-like infiltrate of lymphocytes within the superficial dermis and marked 
epidermotropism of atypical lymphocytes (yellow arrowheads). Lymphocytes showed predominantly 
CD8 positivity especially in the fraction of the epidermotropic lymphocytes (IHC, middle part of the 
image). Abbrev.: CD: cluster of differentiation; TdT: Terminal deoxynucleotidyl transferase ; TCL-1: T-
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cell leukemia/lymphoma protein 1 ; TCR-beta F1: T cell receptor beta locus; TIA1: TIA1 cytotoxic 
granule associated RNA binding protein 
 
Figure 3: A) MF relapse after autologous SCT. Clinical appearance of the skin lesions. B) Durable 
complete remission upon interferon alfa-2a maintenance therapy. C) Correlation of T cell receptor 
(TCR)-γ clonality in multiple skin and brain lesions. All patient’s skin and brain lesions (skin biopsy No. 
1 & 2 before autoSCT, brain biopsy No. 1 & 2 before autoSCT and skin biopsy of recurrent lesion after 
autoSCT) display an identical clear clonal T-cell population (167 base pairs; bp/Vγ9 + Jγ 1.3/2.3 ), no 
clonally rearranged T cells were found in patient’s blood. Results from EuroClonality (BIOMED-2) TCR 
assay, with primers targeting all Vγ1-11 genes and all Jγ exons.  All assays were performed in 
duplicates with lower (HEX/B) and higher (HEX/B+) DNA concentration.  
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